Significance of the c-erbB family of receptor tyrosine kinases in metastatic cancer and their potential as targets for immunotherapy.
Overexpression of members of the type 1 receptor tyrosine kinase (c-erbB) family has been documented in many types of cancer. In the case of c-erbB1 (epidermal growth factor receptor) and c-erbB2, this has been closely linked with poor prognosis, and in particular is apparently associated with an invasive/metastatic phenotype and relative insensitivity to conventional therapies. The cell surface location of these molecules renders them attractive targets for a variety of immunotherapeutic strategies, some of which are showing promise in preclinical and early clinical trials.
Eccles
S A
SA
Section of Immunology, Institute of Cancer Research, Sutton, UK.
Modjtahedi
H
H
Box
G
G
Court
W
W
Sandle
J
J
Dean
C J
CJ
D000818:Animals; D066246:ErbB Receptors / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D009369:Neoplasms / Q000235:genetics / Q000628:therapy* / Q000648:ultrastructure*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000187:drug effects / Q000235:genetics / Q000502:physiology*
D066246:ErbB Receptors; D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases